Clinical utility of treprostinil and its overall place in the treatment of pulmonary arterial hypertension

Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine

Volumn 6, Issue 1, 2011, Pages 41-50

  Mirza, Shireen ^a   Foley, Raymond J ^a  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

Epoprostenol; Hemodynamics; New York heart association functional class; Prostanoids; Pulmonary arterial hypertension; Six minute walk distance; Treprostinil

Indexed keywords

ILOPROST; PLACEBO; PROSTACYCLIN; UNIPROST; WARFARIN;

ARM SWELLING; BLOODSTREAM INFECTION; BONE PAIN; CONTINUOUS INFUSION; COUGHING; DIARRHEA; DISTRIBUTION VOLUME; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EDEMA; GASTROINTESTINAL SYMPTOM; HEADACHE; HOT FLUSH; HUMAN; HYPOTENSION; INJECTION SITE CONTUSION; INJECTION SITE INFECTION; INJECTION SITE PAIN; INJECTION SITE SWELLING; JAW PAIN; MAXIMUM PLASMA CONCENTRATION; MYALGIA; NAUSEA; PULMONARY HYPERTENSION; REVIEW; SEPSIS; SIDE EFFECT; SINGLE DRUG DOSE; SKELETON MALFORMATION; SKIN REDNESS; SKIN TINGLING; SYNCOPE; THROAT IRRITATION; THROMBOCYTOPENIA; TREATMENT OUTCOME; TRISMUS; VASODILATATION; VOMITING;

EID: 84864614571     PISSN: 11795484     EISSN: 11795484     Source Type: Journal    
DOI: 10.4137/CCRPM.S8678     Document Type: Review

References (34)

1. Gilbert E, D'Alonzo D, Robyn J, Barst M, Stephen M, Ayres M, et al. Survival in patients with primary pulmonary hypertension. Annals of Internal Medicine. 1991;115:343-349.
2. Laliberte K, Arneson C, Jeffs R, Hunt T, Wade M. Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteers. Journal of Cardiovascular Pharmacology. Aug 2004;44(2):209-214.
3. Widlitz AC, McDevitt S, Ward GR, Krichman A. Practical aspects of continuous intravenous treprostinil therapy. Critical Care Nurse. Apr 2007;27(2): 41-42, 44-5,47-50; quiz 51.
4. Whittaker N, Bunting S, Salmon J, et al. The chemical structure of prosta-glandin X (prostacyclin). Prostaglandins. Dec 1976;12(6):915-928.
5. Bhattacharya M, Peri KG, Almazan G, et al. Nuclear localization of prosta-glandin E2 receptors. Proceedings of the National Academy of Sciences of the United States of America. Dec 22, 1998;95(26):15792-15797.
6. Falcetti E, Flavell DM, Staels B, Tinker A, Haworth SG, Clapp LH. IP receptor-dependent activation of PPARgamma by stable prostacyclin analogues. Biochemical and Biophysical Research Communications. Sep 7, 2007;360(4):821-827.
7. Wharton J, Davie N, Upton PD, Yacoub MH, Polak JM, Morrell NW. Prostacyclin analogues differentially inhibit growth of distal and proximal human pulmonary artery smooth muscle cells. Circulation. Dec 19, 2000; 102(25):3130-3136.
8. McSwain CS, Benza R, Shapiro S, et al. Dose proportionality of treprostinil sodium administered by continuous subcutaneous and intravenous infusion. Journal of Clinical Pharmacology. Jan 2008;48(1):19-25.
9. Remodulin-Full Prescribing Information. 2011.
10. Tycaso-Full Prescribing Information. 2011.
11. Badesch DB, Abman SH, Simonneau G, Rubin LJ, McLaughlin VV. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest. Jun 2007;131(6):1917-1928.
12. Wade M, Hunt TL, Lai AA. Effect of continuous subcutaneous trepros-tinil therapy on the pharmacodynamics and pharmacokinetics of warfarin. Journal of Cardiovascular Pharmacology. Jun 2003;41(6):908-915.
13. CDC. Bloodstream Infections Among Patients Treated with Intravenous Epoprostenol or Intravenous Treprostinil for Pulmonary Arterial Hypertension-Seven Sites, United States, 2003-2006. 2007:170-172.
14. McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. Journal of the American College of Cardiology. May 4, 2010; 55(18):1915-1922.
15. Benza RL, Seeger W, McLaughlin VV, et al. Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension. The Journal of Heart and Lung Transplantation: The Offcial publication of the International Society for Heart Transplantation. Dec 2011;30(12):1327-1333.
16. Corp. UT. TYVASO- Full Prescribing Information. 2011.
17. O'Grady J, Warrington S, Moti MJ, et al. Effects of intravenous infusion of prostacyclin (PGI2) in man. Prostaglandins. Feb 1980;19(2):319-332.
18. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. The New England Journal of Medicine. Feb 1, 1996;334(5): 296-302.
19. McLaughlin V V, Genthner DE, Panella MM, Rich S. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. The New England Journal of Medicine. Jan 29, 1998;338(5):273-277.
20. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epo-prostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Annals of Internal Medicine. Mar 21, 2000;132(6):425-434.
21. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. American Journal of Respiratory and Critical Care Medicine. Mar 15, 2002;165(6):800-804.
22. Barst RJ, Galie N, Naeije R, et al. Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. The European respiratory Journal: Offcial Journal of the European Society for Clinical Respiratory Physiology. Dec 2006;28(6):1195-1203.
23. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Annals of internal medicine. Sep 1, 1991;115(5):343-349.
24. Lang I, Gomez-Sanchez M, Kneussl M, et al. Effcacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension. Chest. Jun 2006;129(6):1636-1643.
25. Tapson VF, Gomberg-Maitland M, McLaughlin VV, et al. Safety and effcacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial. Chest. Mar 2006;129(3): 683-688.
26. Hiremath J, Thanikachalam S, Parikh K, et al. Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial. The Journal of Heart and Lung Transplantation: The Offcial Publication of the International Society for Heart Transplantation. Feb 2010;29(2):137-149.
27. Bourge RC, Safdar Z, Benza RL, et al. Safely Transitioning from Inhaled Iloprost to Inhaled Treprostinil Sodium -Results from a Multicenter Open-Label Study in Patients with Pulmonary Arterial Hypertension. 2011 PH Professional Network Symposium; 2011.
28. Corp. UT. FREEDOM-C Trial of Oral treprostinil in Pulmonary Arterial Hypertension Fails to Meet Primary Endpoint. 2008.
29. Corp. UT. FREEDOM-M TRIAL of Oral Treprostinil in Pulmonary Hypertension Meets Primary Endpoint. 2011.
30. Corp. UT. FREEDOM-C(2) Trial of Oral Treprostinil in Pulmonary Arterial Hypertension Does Not Meet Primary Endpoint. 2011.
31. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation. Apr 28, 2009; 119(16):2250-2294.
32. Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). European Heart Journal. Oct 2009;30(20):2493-2537.
33. Barst RJ, Rubin LJ, McGoon MD, Caldwell EJ, Long WA, Levy PS. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Annals of internal medicine. Sep 15, 1994; 121(6):409-415.
34. Gomberg-Maitland M, Tapson VF, Benza RL, et al. Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension. American Journal of Respiratory and Critical Care Medicine. Dec 15, 2005;172(12):1586-1589.